ATXN2 and amyotrophic lateral sclerosis: Here, we present a FACS-based CRISPR screen to uncover numerous regulators of ataxin-2 levels—a validated target for ALS and SCA2 based on human genetics—including genes encoding several subunits of lysosomal v-ATPases for which small-molecule drugs are available.